Phase 1 Cystic Fibrosis Trial, Recruiting (NCT07283770)

Phase 1 Cystic Fibrosis Trial, Recruiting NCT07283770 Sponsor: Vertex Pharmaceuticals Incorporated Condition: Cystic Fibrosis

Printed from Voxsanity (voxsanity.com.au) — NCT07283770 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Cystic Fibrosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Your body mass index (BMI) must be between 18.0 and 32.0 (this is a measure of body weight relative to height — you can check yours online with a BMI calculator)
You must weigh more than 50 kilograms (approximately 110 pounds)
You must be male or female and not able to become pregnant (confirm with trial site for what this means in your specific situation)

Who may not be able to join:

You have had a fever or any other recent illness that has not completely cleared up within the last 14 days before starting the study
You have any health condition that could affect how your body absorbs medication (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 617-341-6777

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07283770

Sponsor: Vertex Pharmaceuticals Incorporated

Phase: Phase 1

Status: Recruiting

Condition: Cystic Fibrosis

Trial contact: 617-341-6777

More information: https://clinicaltrials.gov/study/NCT07283770

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Your body mass index (BMI) must be between 18.0 and 32.0 (this is a measure of body weight relative to height — you can check yours online with a BMI calculator)
You must weigh more than 50 kilograms (approximately 110 pounds)
You must be male or female and not able to become pregnant (confirm with trial site for what this means in your specific situation)

Who may not be able to join:

You have had a fever or any other recent illness that has not completely cleared up within the last 14 days before starting the study
You have any health condition that could affect how your body absorbs medication (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Vertex Pharmaceuticals Incorporated

Registry

ClinicalTrials.gov

Start date

9 December 2025

Est. completion

19 November 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs); Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs); Part C: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov